Will Genome Modifications Define Next-Gen AAV Vectors?
UF researcher Arun Srivastava, Ph.D., a gene therapy pioneer, shares his expert perspective on genome-modified AAV vectors, offering insights into how next-generation viral therapies may be shaped by precision genetic engineering.
American Association for the Advancement of Science Names 14 UF Faculty Lifetime Fellows
The American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the Science family of journals, has elected 14 faculty from the University of Florida to its newest class.
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics, a leading ophthalmic gene therapy company that acquired UF startup AGTC to save and restore the vision of patients with blinding retinal diseases, announced it has raised $170 million in Series B funding.
Tech Tuesday: A Helpful Virus
In this week's Tech Tuesday for WCJB TV20, UF Innovate's Melanie Morón interviews Dr. Arun Srivastava from the University of Florida's College of Medicine Department of Pediatrics who introduces us to a virus -- the adeno-associated virus or AAV -- that cures rather than infects. AAV has cured nine human diseases. The FDA has approved five drugs using it. And Dr. Srivastava's lab of scientists is working to make the vectors more efficient.
